We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Tests for Detecting Antioxidant and Inflammation Levels Could Diagnose Breast Cancer

By LabMedica International staff writers
Posted on 07 Apr 2022

Breast cancer is the most prevalent cancer in the world. More...

Identifying new diagnostic techniques is of major importance to efforts that aim to minimize the disease’s devastating effects. Now, a new study that analyzes levels of antioxidants and stress markers in the blood could lead to a new diagnostic tool for breast cancer.

Researchers from the University of Lahore (Lahore, Pakistan) explored the role that inflammatory and stress markers may play in the development and progression of breast cancer. The research team examined blood samples from premenopausal women diagnosed with breast cancer. When compared to age-matched controls without cancer, the breast cancer patients had significantly increased levels of inflammatory markers.

Among the overexpressed markers were the pro-inflammatory protein interleukin-1, matrix metalloproteinase 9 - an enzyme that is overexpressed in several diseases - and heat shock protein 27. This protein acts as an antioxidant that typically prevents or reduces cell death. However, in some disease states - such as cancer - heat shock protein 27 has been found to be both protective and destructive. In addition, the breast cancer group had low levels of protective compounds such as vitamins A, C and D, catalase - an enzyme that protects cells from oxidative stress - and the antioxidants superoxide dismutase and glutathione.

“The breast cancer pathophysiology included an overbalance of oxidants or stress markers and an underbalance of antioxidants,” said Samina Malik, MBBS, MPhil, first author of the study. This proportion of pro- and anti-inflammatory components may play “a crucial role in the metastasis of breast cancer” and may be useful as a diagnostic marker for the disease, according to the researchers.

Related Links:
University of Lahore 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.